Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Transcode Therapeutics Inc RNAZ

Healthcare Biotechnology
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique... see more

Recent & Breaking News (NDAQ:RNAZ)

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

GlobeNewswire March 6, 2024

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

GlobeNewswire February 20, 2024

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

GlobeNewswire January 31, 2024

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

GlobeNewswire January 29, 2024

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

GlobeNewswire January 22, 2024

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

GlobeNewswire January 18, 2024

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

GlobeNewswire January 12, 2024

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

GlobeNewswire January 11, 2024

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

GlobeNewswire January 4, 2024

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

GlobeNewswire December 12, 2023

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

GlobeNewswire December 5, 2023

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

GlobeNewswire December 4, 2023

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

GlobeNewswire November 30, 2023

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

GlobeNewswire November 14, 2023

TransCode Therapeutics Withdraws Public Offering

GlobeNewswire October 30, 2023

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

GlobeNewswire October 27, 2023

TransCode Therapeutics Announces Public Offering of Common Stock

GlobeNewswire October 26, 2023

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

GlobeNewswire October 26, 2023

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

GlobeNewswire October 24, 2023

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

GlobeNewswire October 16, 2023